Following these transactions, Hsu’s direct holdings in Immix Biopharma increased to 893,000 shares. Additionally, Hsu holds indirect interests through entities where he has voting and disposal rights, including VERITAS LIBERABIT VOS, LLC and Signature Collection Properties, LLC. The filing indicates that Hsu disclaims beneficial ownership of the securities held by these entities, except for his pecuniary interest. InvestingPro analysis shows the company maintains a healthy balance sheet with more cash than debt and a strong current ratio of 3.47x, though it’s currently experiencing rapid cash burn. Get access to 8 more key ProTips and detailed financial metrics with InvestingPro. InvestingPro analysis shows the company maintains a healthy balance sheet with more cash than debt and a strong current ratio of 3.47x, though it’s currently experiencing rapid cash burn. Get access to 8 more key ProTips and detailed financial metrics with InvestingPro.
Following these transactions, Hsu’s direct holdings in Immix Biopharma increased to 893,000 shares. Additionally, Hsu holds indirect interests through entities where he has voting and disposal rights, including VERITAS LIBERABIT VOS, LLC and Signature Collection Properties, LLC. The filing indicates that Hsu disclaims beneficial ownership of the securities held by these entities, except for his pecuniary interest.
In other recent news, Immix Biopharma has reported promising results from the NEXICART-2 trial of its CAR-T cell therapy, NXC-201. The therapy has shown a 75% complete response rate in patients with relapsed/refractory AL Amyloidosis. The company has also expanded its U.S. Phase 1b/2 study of CAR-T therapy NXC-201 to include three new clinical trial sites. H.C. Wainwright has maintained a Buy rating for Immix, highlighting the trials’ progress and the potential of NXC-201. The company has appointed Crowe LLP as its new auditor and received an orphan drug designation from the European Commission for NXC-201. Dr. Raymond (NS:RYMD) Comenzo, an expert in AL Amyloidosis, has joined the Scientific Advisory Board of Immix Biopharma’s subsidiary Nexcella. These developments underscore Immix Biopharma’s ongoing efforts in the biopharmaceutical industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.